Jianbo Xianyu1, Jiafu Feng2, Yuwei Yang3, Jie Tang3, Gang Xie4, Lingying Fan5. 1. Department of General Surgery, The Affiliated Mianyang Central Hospital of Southwest Medical University, 621000, Sichuan, China. 2. Department of Laboratory Medicine, The Affiliated Mianyang Central Hospital of Southwest Medical University, 621000, Sichuan, China. Electronic address: mychml2007@aliyun.com. 3. Department of Laboratory Medicine, The Affiliated Mianyang Central Hospital of Southwest Medical University, 621000, Sichuan, China. 4. Department of Clinical Pathology, The Affiliated Mianyang Central Hospital of Southwest Medical University, 621000, Sichuan, China. 5. Department of Laboratory Medicine, The Affiliated Mianyang Central Hospital of Southwest Medical University, 621000, Sichuan, China; Laboratory Medicine, Southwest Medical University, 646000 Luzhou, China.
Abstract
OBJECTIVE: This study aims to explore the correlation of oxidative stress (OxS) in patients with chronic hepatitis B (CHB) and the disease severity with HBV genotypes and drug resistance mutations. METHODS: A total of 296 patients with CHB were enrolled into the study. PCR-reverse dot-blot hybridization was used to detect the HBV genotypes (B, C, and D) and the drug resistance-causing HBV mutant genes. In addition, the total oxidative stress (TOS) and total antioxidant status (TAS) were determined, and oxidative stress index (OSI) was calculated and compared. RESULTS: Serum levels of TOS and OSI, the B/C ratio, and drug resistance mutation rate were increased along with the elevated disease severity degree (CHB<HBC<HCC) (P < 0.05), while the serum TAS level showed the opposite trend (though there was no statistical difference between patients at the CHB and HBC stages). Moreover, patients with drug resistance-causing HBV mutation had higher serum TOS and OSI levels, while lower serum TAS levels (P < 0.05), compared with patients without mutations. Furthermore, mutation site numbers were positively correlated with the disease severity degree (γ = 0.614, P < 0.001). CONCLUSION: There is oxidative damage in patients with HBV-induced liver disease, and the damage degree is correlated with the HBV genotype and drug resistance mutation. Oxidative stress might be a useful indicator of the progression of HBV-induced liver disease in patients.
OBJECTIVE: This study aims to explore the correlation of oxidative stress (OxS) in patients with chronic hepatitis B (CHB) and the disease severity with HBV genotypes and drug resistance mutations. METHODS: A total of 296 patients with CHB were enrolled into the study. PCR-reverse dot-blot hybridization was used to detect the HBV genotypes (B, C, and D) and the drug resistance-causing HBV mutant genes. In addition, the total oxidative stress (TOS) and total antioxidant status (TAS) were determined, and oxidative stress index (OSI) was calculated and compared. RESULTS: Serum levels of TOS and OSI, the B/C ratio, and drug resistance mutation rate were increased along with the elevated disease severity degree (CHB<HBC<HCC) (P < 0.05), while the serum TAS level showed the opposite trend (though there was no statistical difference between patients at the CHB and HBC stages). Moreover, patients with drug resistance-causing HBV mutation had higher serum TOS and OSI levels, while lower serum TAS levels (P < 0.05), compared with patients without mutations. Furthermore, mutation site numbers were positively correlated with the disease severity degree (γ = 0.614, P < 0.001). CONCLUSION: There is oxidative damage in patients with HBV-induced liver disease, and the damage degree is correlated with the HBV genotype and drug resistance mutation. Oxidative stress might be a useful indicator of the progression of HBV-induced liver disease in patients.
Authors: Mihnea Marian Pomacu; Maria Diana Trașcă; Vlad Pădureanu; Ana Maria Bugă; Ana Marina Andrei; Elena Camelia Stănciulescu; Ileana Monica Baniță; Dumitru Rădulescu; Cătălina Gabriela Pisoschi Journal: Exp Ther Med Date: 2021-04-14 Impact factor: 2.447
Authors: Magda Rybicka; Anna Woziwodzka; Alicja Sznarkowska; Tomasz Romanowski; Piotr Stalke; Marcin Dręczewski; Eloi R Verrier; Thomas F Baumert; Krzysztof Piotr Bielawski Journal: Cancers (Basel) Date: 2020-11-07 Impact factor: 6.639